Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 60Neoplasms 41Carcinoma, Non-Small-Cell Lung 32Ovarian Neoplasms 27Neoplasm Metastasis 22Glioblastoma 19Lung Neoplasms 17Fallopian Tube Neoplasms 16Colonic Neoplasms 16Breast Neoplasms 16Rectal Neoplasms 15Pancreatic Neoplasms 15Carcinoma, Renal Cell 13Carcinoma, Hepatocellular 12Stomach Neoplasms 10Glioma 10Carcinoma, Ovarian Epithelial 8Solid Cancers 7Sarcoma 7Melanoma 7Liver Neoplasms 7Brain Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Solid Tumors 6Uterine Cervical Neoplasms 5Recurrence 5Lymphoma, Non-Hodgkin 5Astrocytoma 5Advanced Cancer 5Triple Negative Breast Neoplasms 4

Interventions

devimistat 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × C04.588.274.476.411.307 × Bevacizumab × Clear all
NCT05070104 2023-09-13

CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Cornerstone Pharmaceuticals

Phase 1 Withdrawn

C04.588.274.476.411.307

Data powered by HemOnc (CC BY 4.0) Colophon âš¡